Leticia Ribeiro de Assis

Dr. Leticia Ribeiro de Assis


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
PRPaulo Ricardo Pimenta Da Silva Ramos
Paulo Ricardo Pimenta Da Silva Ramos
MMMelina Mottin
Melina Mottin
CLCaroline Sprengel Lima
Caroline Sprengel Lima
LALeticia Ribeiro de Assis
Leticia Ribeiro de Assis
KOKetllyn Zagato de Oliveira
Ketllyn Zagato de Oliveira
CACarolina Andrade
Carolina Andrade
Although the past epidemic of Zika virus (ZIKV) resulted in severe neurological consequences for infected infants and adults, there are still no approved drugs to treat ZIKV infection. In this study, we applied computational approaches to screen an in-house database of 77 natural and semi-synthetic compounds against ZIKV NS5 RNA-dependent RNA-polymerase (NS5 RdRp), an essential protein for viral RNA elongation during the replication process. For this purpose, we integrated computational approaches such as binding-site conservation, chemical space analysis and molecular docking. As a result, we prioritized nine virtual hits for experimental evaluation. Enzymatic assays confirmed that pedalitin and quercetin inhibited ZIKV NS5 RdRp with IC50 values of 4.1 and 0.5 µM, respectively. Moreover, pedalitin also displayed antiviral activity on ZIKV infection with an EC50 of 19.28 µM cell-based assays, with low toxicity in Vero cells (CC50 = 83.66 µM) and selectivity index of 4.34. These results demonstrate the potential of the natural compounds pedalitin and quercetin as candidates for structural optimization studies towards the discovery of new anti-ZIKV drug candidates.

26 November 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
NBNíura Madalena Bila
Níura Madalena Bila
CVCarolina Orlando Vaso
Carolina Orlando Vaso
JBJenyffie Araujo Belizario
Jenyffie Araujo Belizario
LALeticia Ribeiro de Assis
Leticia Ribeiro de Assis
Luis RegasiniLuis Regasini
Luis Regasini
Maria José Soares Mendes GianniniMaria José Soares Mendes Giannini
Maria José Soares Mendes Giannini
Background: Photodynamic therapy (PDT) is a treatment modality that uses light to activate a photosensitizing agent, destroying target cells. The growing awareness of the necessity to reduce or eliminate the use of mammals in research has prompted the search for safer toxicity testing models aligned with the new global guidelines and compliant with the relevant regulations. Objective: The objective of this study was to assess the impact of PDT on alternative models to mammals, including in vitro three-dimensional (3D) cultures and in vivo, in invertebrate animals, utilizing a potent photosensitizer, 2-hydroxychalcone. Methods: Cytotoxicity was assessed in two cellular models: monolayer (2D) and 3D. For this purpose, spheroids of two cell lines, primary dermal fibroblasts (HDFa) and adult human epidermal cell keratinocytes (HaCat), were developed and characterized following criteria on cell viability, shape, diameter, and number of cells. The survival percentages of Caenorhabditis elegans and Galleria mellonella were evaluated at 1 and 7 days, respectively. Results: The findings indicated that all the assessed platforms are appropriate for investigating PDT toxicity. Furthermore, 2-hydroxychalcone demonstrated low toxicity in the absence of light and when mediated by PDT across a range of in vitro (2D and 3D cultures) and in vivo (invertebrate animal models, including G. mellonella and C. elegans) models. Conclusion: There was a strong correlation between the in vitro and in vivo tests, with similar toxicity results, particularly in the 3D models and C. elegans, where the concentration for 50% viability was approximately 100 µg/mL.